{"id":"W2589777133","doi":"10.1200/jco.2013.31.6_suppl.5","title":"Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Abiraterone acetate; Internal medicine; Prostate cancer; Interim analysis; Hazard ratio; Clinical endpoint; Prednisone; Placebo; Progression-free survival; Gastroenterology; Asymptomatic; Urology; Chemotherapy; Androgen deprivation therapy; Oncology; Population; Randomized controlled trial; Cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006796186,0.001599141,0.002455975,0.0005360497,0.0003620578,0.001284639,0.0008188725,0.0008972303,0.005305809],"category_scores_gemma":[0.005639223,0.0006626554,0.003526153,0.0004410103,0.0003351296,0.0008274237,0.0006359533,0.00297561,0.0007969577],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005102783,"about_ca_system_score_gemma":0.001249537,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005526374,"about_ca_topic_score_gemma":0.00209646,"domain_scores_codex":[0.9977737,0.001367569,0.0001185812,0.0002218518,0.0002728355,0.0002453786],"domain_scores_gemma":[0.9974004,0.0008419414,0.0006476077,0.0004154423,0.0002023457,0.0004922409],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9221842,0.004220645,0.005567749,0.0007775094,0.009433902,0.0001563349,0.0001116843,0.002982271,0.005983109,0.0005230625,0.01255415,0.03550544],"study_design_scores_gemma":[0.7469788,0.1560039,0.04494186,0.0001563832,0.02013416,0.0003649234,0.00006085173,0.006070063,0.004993747,0.001525355,0.01867237,0.00009756665],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9110794,0.01014157,0.01377098,0.002050068,0.002180221,0.01467538,0.03086896,0.001005907,0.01422751],"genre_scores_gemma":[0.9373624,0.002385107,0.01150027,0.002701889,0.0005088742,0.01141521,0.02330782,0.0001963757,0.01062214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006796186,"threshold_uncertainty_score":0.03594208,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08645765738220536,"score_gpt":0.4905051951186309,"score_spread":0.4040475377364255,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}